Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma

Mostrar otras versiones (1)

BACKGROUND: Trastuzumab has recently shown efficacy in the treatment of HER2-positive advanced gastric adenocarcinoma. Although antibody-based therapies target the metastatic disease, HER2 status is usually evaluated in the primary tumour because metastatic sites are rarely biopsied. The aim of this...

Descripción completa

Detalles Bibliográficos
Autores principales: Bozzetti, C, Negri, F V, Lagrasta, C A, Crafa, P, Bassano, C, Tamagnini, I, Gardini, G, Nizzoli, R, Leonardi, F, Gasparro, D, Camisa, R, Capelli, S, Silini, E M, Ardizzoni, A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3101935/
https://www.ncbi.nlm.nih.gov/pubmed/21487407
http://dx.doi.org/10.1038/bjc.2011.121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3101935/
https://www.ncbi.nlm.nih.gov/pubmed/21487407
http://dx.doi.org/10.1038/bjc.2011.121

Ejemplares similares